


Amendments to the Claims

The below listing of claims is intended to replace all prior versions of the claims in the application.

1. (Currently Amended) A benzisothiazole-3(2H)-one compound of formula (I)



(I)

wherein;

R₁ is the group ~~(C₅-C₁₂)alkyl~~ (C₅-C₇)alkyl, (C₄-C₁₂)haloalkyl, (C₄-C₁₂)alkenyl, (C₄-C₁₂)alkynyl, (C₁-C₈)alkylcycloalkyl, (C₃-C₈)cycloalkyl, (C₁-C₁₂)alkylheterocyclic radical, (C₃-C₄)alkylaryl, or aryl wherein the aryl or ~~heterocyclic~~ heterocyclic group is ~~optionally~~ substituted with ~~one to 2~~ one to 2 or 3 groups independently selected from (C₁-C₁₂)alkyl, (C₂-C₁₂)alkenyl, (C₁-C₁₂)alkoxy, (C₁-C₈)alkylcycloalkyl, ~~halo~~, and (C₁-C₁₂)haloalkyl;

R₂ is hydrogen;

R₃, R₄, R₅, and R₆, are each independently selected from hydrogen, (C₂-C₁₂)alkyl, (C₁-C₁₂)haloalkyl, (C₁-C₁₂)alkoxyalkyl, (C₁-C₁₀)thioalkyl, hydroxy, (C₂-C₁₂)alkenyl, (C₂-C₁₂)alkynyl, (C₁-C₁₂)alkylaryl, (C₁-C₁₂)alkylcycloalkyl, (C₁-C₁₂)alkylheterocyclic, C(O)C₁-C₆ alkyl, C(O)OC₁-C₆alkyl, phenyl or aryl; wherein each of alkyl, alkenyl, phenyl or aryl groups may be optionally substituted with one to three substituents selected from halo, amino, halo, C₁-C₆ alkyl, ~~(C₂-C₆)alkenyl~~ (C₂-C₆)alkenyl, (C₁-C₆)haloalkyl; or a pharmaceutically acceptable salt, solvate or isomer thereof.

2. (Canceled)


3. (Currently Amended) A compound according to Claim 1 wherein R_1 , is ~~(C₅-C₈)alkyl~~ (C₅-C₇)alkyl, (C₄-C₆)alkenyl, -O-(C₁-C₃ alkyl), (C₃-C₄)alkylcycloalkyl, -CF₃, or aryl.

4. (Currently Amended) A compound according to Claim 1 wherein R_1 , is benzyl substituted with 0, 1 or 2 substituents selected from (C₁-C₆)alkyl, (C₂-C₄)alkenyl, -O-(C₁-C₃ alkyl), (C₁-C₄)alkylcycloalkyl, and -CF₃,

5. (Original) A compound of Claim 1 wherein R_3 , R_4 , R_5 and R_6 are independently selected from the group consisting of (C₁-C₄)alkyl, (C₂-C₄)alkenyl, -O-(C₁-C₃ alkyl), -S-(C₁-C₃ alkyl), (C₅-C₁₂)cycloalkyl, COOH, C(O)(C₁-C₃ alkyl), C(O)O(C₁-C₃ alkyl), -CF₃, and halo.

6. (Original) The compound of Claim 1 wherein R_5 is the group represented by COOH, C(O)(C₁-C₃ alkyl), C(O)O(C₁-C₃ alkyl), chloro, bromo or CF₃.

7. (Currently Amended) A compound of formula (I)



wherein R_1 through R_6 are selected to provide a compound selected from the group consisting of:

~~3-Oxo-3H-benzo[d]isothiazole-2-carboxylic acid ethylamide;~~

~~3-Oxo-3H-benzo[d]isothiazole-2-carboxylic acid propylamide;~~

3-Oxo-3H-benzo[d]isothiazole-2-carboxylic acid allylamide;

3-Oxo-3H-benzo[d]isothiazole-2-carboxylic acid pentylamide;


3-Oxo-3H-benzo[d]isothiazole-2-carboxylic acid hexylamide;

3-Oxo-3H-benzo[d]isothiazole-2-carboxylic acid (5-methyl-hexyl)-amide;


Docket No. X-13055 (US)

~~3-Oxo-3H-benzo[d]isothiazole-2-carboxylic acid dodecylamide;~~
3-Oxo-3H-benzo[d]isothiazole-2-carboxylic acid cyclohexylamide;
3-Oxo-3H-benzo[d]isothiazole-2-carboxylic acid 2-methyl-benzylamide;
3-Oxo-3H-benzo[d]isothiazole-2-carboxylic acid 3-methyl-benzylamide;
3-Oxo-3H-benzo[d]isothiazole-2-carboxylic acid 4-methyl-benzylamide;
3-Oxo-3H-benzo[d]isothiazole-2-carboxylic acid 2-ethyl-6-methyl-benzylamide;
3-Oxo-3H-benzo[d]isothiazole-2-carboxylic acid 2-isopropyl-6-methyl-benzylamide;
3-Oxo-3H-benzo[d]isothiazole-2-carboxylic acid phenethylamide;
3-Oxo-3H-benzo[d]isothiazole-2-carboxylic acid (2-thiophen-2-yl-ethyl)-amide;
3-Oxo-3H-benzo[d]isothiazole-2-carboxylic acid (3-phenyl-propyl)-amide;
3-Oxo-3H-benzo[d]isothiazole-2-carboxylic acid (4-phenyl-butyl)-amide;
3-Oxo-3H-benzo[d]isothiazole-2-carboxylic acid (4-cyclohexyl-butyl)-amide;
5-Methyl-3-oxo-3H-benzo[d]isothiazole-2-carboxylic acid butylamide;
6-Chloro-3-oxo-3H-benzo[d]isothiazole-2-carboxylic acid propylamide;
6-Chloro-3-oxo-3H-benzo[d]isothiazole-2-carboxylic acid isopropylamide;
6-Chloro-3-oxo-3H-benzo[d]isothiazole-2-carboxylic acid butylamide;
6-Chloro-3-oxo-3H-benzo[d]isothiazole-2-carboxylic acid hexylamide;
6-Chloro-3-oxo-3H-benzo[d]isothiazole-2-carboxylic acid cyclohexylamide; and
~~6-Chloro-3-oxo-3H-benzo[d]isothiazole-2-carboxylic acid benzylamide.~~


8. (Original) A benzisothiazole-3(2H)-one compound represented by the formulae (C1), (C2), (C3), or (C4):




(C1),



(C2),




(C3),



(C4).

9. (Original) A pharmaceutical formulation comprising a benzisothiazole-3(2H)-one compound of formula I together with a pharmaceutically acceptable carrier or diluent.


10. (Currently Amended) A method of inhibiting hepatic lipase and/or endothelial lipase activity using a therapeutically effective amount of benzisothiazole-3(2H)-one compound of formula I, wherein R_1 - R_6 are as defined in claim 1



or a pharmaceutical acceptable salt, solvate, or prodrug thereof.

11. (Original) A method of treating a mammal to alleviate the pathological effects of elevated hepatic lipase and/or endothelial lipase activity; comprising administering to said mammal a therapeutically effective amount of a benzisothiazole-3(2H)-one compound according to Claim 1.

12. (Currently Amended) A pharmaceutical formulation containing a therapeutically effective amount of the compound of formula 1, wherein R_1 - R_6 are defined as in claim 1



useful formulated for the treatment and/or amelioration of the effect of elevated hepatic lipase and/or endothelial lipase activity.

13-15. (Canceled)

16. (New) The method of claim 10 wherein the benzisothiazole-3(2H)-one compound is formulated with a with a pharmaceutically acceptable carrier or diluent.

17, (New) The method of claim 11 wherein the benzisothiazole-3(2H)-one compound is formulated with a with a pharmaceutically acceptable carrier or diluent.